Go to the list of all blogs
Alicia's Avatar
published in Blogs
May 28, 2026
Why Is Photronics, Inc. (PLAB) Stock Down -32% Today?

Why Is Photronics, Inc. (PLAB) Stock Down -32% Today?

Key Takeaways

  • PLAB shares plunged 32.46% after the company reported second-quarter fiscal 2026 results that missed analyst estimates on both earnings and revenue.
  • Reported EPS of $0.42 fell short of the $0.53 consensus, while revenue came in below expectations at approximately $210 million.
  • Management highlighted delays in customer designs, supply chain strains, and increased uncertainty in the semiconductor cycle as key factors weighing on the outlook.
  • Trading volume surged to more than five times the average, reflecting a sharp negative market reaction to the earnings miss.
  • The broader semiconductor equipment sector showed mixed performance, with PLAB diverging sharply lower from major indices.
  • Investors will focus on management commentary during the earnings call and any updates to fiscal 2026 guidance.

Company Background and the Initial Stock Reaction

Photronics, Inc. (PLAB) manufactures photomasks used in the production of semiconductors and flat-panel displays. The stock fell sharply in today’s session, closing at $36.14 compared with the prior session’s close of $53.51. The decline of 32.46% was driven primarily by disappointing quarterly results released before the market open. From what I see, the reaction was swift and decisive once the numbers hit the tape.

Breaking Down the Q2 Earnings Miss

Photronics reported fiscal second-quarter results that missed Wall Street forecasts. Earnings per share came in at $0.42 versus the expected $0.53, while revenue fell short of the $216 million consensus. The shortfall reflected softer demand in certain integrated-circuit segments and customer design delays that affected order timing. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry and confirm the relative weakness.

Guidance and Management Commentary

Executives noted ongoing supply-chain pressures and heightened uncertainty in the semiconductor industry. They flagged potential delays in new design ramps and maintained a cautious tone regarding near-term visibility. The combination of the earnings miss and tempered commentary triggered broad selling. One thing that stands out is how quickly sentiment shifted once the tempered outlook was clear.

Market Context and Trading Activity

Volume expanded dramatically to roughly 1.57 million shares, more than five times the recent average, underscoring the intensity of the reaction. While major U.S. indices traded modestly lower, PLAB’s move was outsized and company-specific. The stock broke well below recent support levels and its 50-day moving average. I’m watching this closely to see whether the volume spike signals capitulation or further downside pressure.

Trending AI Robots

As part of my regular process, I often review Tickeron’s Trending AI Robots page to identify the strongest-performing AI trading bots under current market conditions. The platform offers hundreds of AI-powered strategies across thousands of tickers, with featured bots differentiated by trading style, time horizon, and performance metrics. Traders can review live signals and historical results before deploying any strategy. I find it useful for exploring curated options that align with individual risk preferences and market views.

What Comes Next for PLAB

Attention now turns to the company’s earnings conference call and any revisions to full-year guidance. Analysts will monitor updates on design-win momentum and capital-expenditure plans. Key risks include further softening in semiconductor demand, execution on new capacity, and broader macroeconomic pressures affecting customer spending.

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: PLAB

Contributor

Alicia's AvatarAlicia|Beginner

PLAB's RSI Indicator ascending out of oversold territory

The RSI Oscillator for PLAB moved out of oversold territory on September 02, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 26 similar instances when the indicator left oversold territory. In 21 of the 26 cases the stock moved higher. This puts the odds of a move higher at 81%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 16, 2026. You may want to consider a long position or call options on PLAB as a result. In 63 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.

The Moving Average Convergence Divergence (MACD) for PLAB just turned positive on September 18, 2026. Looking at past instances where PLAB's MACD turned positive, the stock continued to rise in 31 of 46 cases over the following month. The odds of a continued upward trend are 67%.

PLAB moved above its 50-day moving average on September 25, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for PLAB crossed bullishly above the 50-day moving average on October 01, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.

Following a +2.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where PLAB advanced for three days, in 215 of 289 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PLAB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.

PLAB broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for PLAB entered a downward trend on September 24, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.405) is normal, around the industry mean (8.078). P/E Ratio (10.854) is within average values for comparable stocks, (161.623). Projected Growth (PEG Ratio) (1.000) is also within normal values, averaging (0.801). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (1.880) is also within normal values, averaging (27.897).

The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating fairly steady price growth. PLAB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 63 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock slightly worse than average.

Notable companies

The most notable companies in this group are Lam Research Corp (NASDAQ:LRCX), Applied Materials (NASDAQ:AMAT), KLA Corporation (NASDAQ:KLAC), Teradyne (NASDAQ:TER), Ambarella (NASDAQ:AMBA).

Industry description

The electronic production equipment industry makes equipment used to produce semiconductors. Such equipment includes wafer fabrication, plasma etching and photo-resist processing equipment. The industry also makes chemical vapor deposition processing systems and photomasks, which are high-purity quartz plates that contain patterns to define integrated circuits layouts. Applied Materials, Inc., Lam Research Corporation, and KLA-Tencor Corporation are examples of electronic production equipment manufacturing companies.

Market Cap

The average market capitalization across the Electronic Production Equipment Industry is 63.66B. The market cap for tickers in the group ranges from 326.86K to 671.68B. ASML holds the highest valuation in this group at 671.68B. The lowest valued company is AVSR at 326.86K.

High and low price notable news

The average weekly price growth across all stocks in the Electronic Production Equipment Industry was 7%. For the same Industry, the average monthly price growth was 13%, and the average quarterly price growth was 19%. INTT experienced the highest price growth at 28%, while SMTK experienced the biggest fall at -30%.

Volume

The average weekly volume growth across all stocks in the Electronic Production Equipment Industry was 15%. For the same stocks of the Industry, the average monthly volume growth was -12% and the average quarterly volume growth was -63%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 63
P/E Growth Rating: 34
Price Growth Rating: 42
SMR Rating: 71
Profit Risk Rating: 59
Seasonality Score: 27 (-100 ... +100)
View a ticker or compare two or three
PLAB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of photomasks used in making semiconductors

Industry ElectronicProductionEquipment

Industry
Electronic Production Equipment
Address
15 Secor Road
Phone
+1 203 775-9000
Employees
1908
Web
https://www.photronics.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.